Capricor Therapeutics announces publication on StealthX Platform

Capricor Therapeutics announced the publication of a preclinical study in Microbiology Spectrum, a leading peer-reviewed scientific journal of the American Society for Microbiology, highlighting the therapeutic potential of its StealthX exosome platform technology to develop a multivalent vaccine against the spike and nucleocapsid SARS-CoV-2 proteins. In this study, exosomes were engineered to express either SARS-CoV-2 spike or nucleocapsid proteins on the surface. When administered individually, both STX-S and STX-N induced a potent humoral and cellular immune response. These effects were obtained with administration of only nanogram amounts of protein and without adjuvant or synthetic lipid nanoparticles. Importantly, preclinical results from murine and rabbit models suggest the combination, STX-S+N, as a single shot, resulted in robust antibody production, potent neutralizing antibodies, a strong T-cell response and a favorable safety profile. These peer-reviewed results which were previously published online on bioRxiv established the prospect of rapidly combining multiple targets in one vaccine and supports exosomes as a suitable delivery vehicle for a variety of therapeutic cargo.